| 3.89 -0.27 (-6.49%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.97 |
1-year : | 5.67 |
| Resists | First : | 4.25 |
Second : | 4.86 |
| Pivot price | 4.1  |
|||
| Supports | First : | 3.27 |
Second : | 2.72 |
| MAs | MA(5) : | 4.09 |
MA(20) : | 3.97 |
| MA(100) : | 3.17 |
MA(250) : | 2.52 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 45.5 |
D(3) : | 49.8 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 4.86 | Low : | 1.26 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CMPX ] has closed above bottom band by 33.4%. Bollinger Bands are 75.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.22 - 4.24 | 4.24 - 4.26 |
| Low: | 3.84 - 3.86 | 3.86 - 3.88 |
| Close: | 4.12 - 4.16 | 4.16 - 4.19 |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Thu, 23 Oct 2025
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Unpacking a 210% Potential Upside in the Biotech Space - DirectorsTalk Interviews
Thu, 16 Oct 2025
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Unveiling a 170% Upside Potential in Biotechnology - DirectorsTalk Interviews
Mon, 01 Sep 2025
Piper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial Update - Yahoo Finance
Tue, 12 Aug 2025
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering - GlobeNewswire
Tue, 12 Aug 2025
Compass Therapeutics prices $120 million public offering of common stock - Investing.com
Tue, 12 Aug 2025
Cancer Drug Developer Compass Therapeutics Secures $120M to Advance Commercial Plans - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 172 (M) |
| Shares Float | 101 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 62.6 (%) |
| Shares Short | 14,820 (K) |
| Shares Short P.Month | 10,250 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.2 % |
| Return on Equity (ttm) | -51.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -8.67 |
| PEG Ratio | 0 |
| Price to Book value | 5.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|